Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China

Table 2 Model predicted long-term clinical outcomes of using direct acting antivirals in China

Study Information	Regimens compared	Predicted reduction in liver sequelae relative to PR therapy
		DCC	HCC	Liver transplant	Liver-related death
Simulating 10000 Chinese CHC patients over a lifetime horizon;	GLE/PIB[57]	-95%	-90%	-95%	-92%
	SOF/VEL[56,57]	-96%	-91%	-96%	-93%
	DCV + ASV[56]	-51%	-48%	-51%	-49%
	O/P/r + D[56]	-59%	-55%	-59%	-57%
	EBR/GZR[56]	-59%	-55%	-59%	-57%
GT1b, 2, 3, 6

ASV: Asunaprevir; CHC: Chronic hepatitis C; DCC: Decompensated cirrhosis; DCV: Daclatasvir; EBR: Elbasvir; GT: Genotype; GZR: Grazoprevir; HCC: Hepatocellular carcinoma; O/P/r + D: Ombitasvir/paritaprevir/ritonavir plus dasabuvir; PR: Pegylated-interferon plus ribavirin; RBV: Ribavirin; SOF: Sofosbuvir; VEL: Velpatasvir.